Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review

Published:2021-06-08 Issue:7 Volume:38 Page:3674-3693
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Arru Caterina,De Miglio Maria Rosaria^ORCID,Cossu Antonio,Muroni Maria Rosaria,Carru Ciriaco,Zinellu Angelo,Paliogiannis Panagiotis

Funder

Fondo di Ateneo per la Ricerca 2020 from the University of Sassari, Italy

Università degli Studi di Sassari

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-021-01796-6.pdf

Reference94 articles.

1. Renrick AN, Dunbar ZT, Shanker A. Update on the current revolution in cancer immunotherapy. Immunotherapy. 2019;11:15–20.

2. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734–6.

3. Rohatgi A, Kirkwood JM. Beyond PD-1: the next frontier for immunotherapy in melanoma. Front Oncol. 2021;11:76.

4. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–5.

5. Olofsson Bagge R, Ny L, Ascierto PA, et al. The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. Melanoma Res. 2021;31:181–5.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrative Bioinformatics Analysis for Targeting Hub Genes in Hepatocellular Carcinoma Treatment;Current Genomics;2024-07-18

2. PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study;Annals of Diagnostic Pathology;2024-04

3. Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care;Cancers;2024-03-14

4. Role of Durvalumab (Anti-PD-L1) in the Management of Mesothelioma: A Systematic Review of the Current Literature;Barw Medical Journal;2023-12-05

5. Efficacy and safety of tislelizumab for malignant solid tumor: a systematic review and meta-analysis of phase III randomized trials;Expert Review of Clinical Pharmacology;2023-10-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3